UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.176-178

2020

Volltextzugriff (PDF)

Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9592-9592

2024

Volltextzugriff (PDF)

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Molecular cancer therapeutics, 2024-08, Vol.23 (8), p.1139-1143

2024

Volltextzugriff (PDF)

Mo1847 THE INFLUENCE OF PERSISTENT ACTIVE INFLAMMATION ON IFX PHARMACOKINETIC MODELING AND DISEASE PROGRESSION ASSESSMENT: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY IN INFLAMMATORY BOWEL DISEASE PATIENTS

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1141-S-1141

2024

Volltextzugriff (PDF)

Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9534-9534

2023

Volltextzugriff (PDF)

Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1

Expert opinion on investigational drugs, 2020-11, Vol.29 (11), p.1179-1185

2020

Volltextzugriff (PDF)

IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21542-e21542

2022

Volltextzugriff (PDF)

Performance of Remsima® Monitor Drug Level versus RIDASCREEN IFX Monitoring in therapeutic drug monitoring of infliximab in patients with inflammatory bowel disease: A study of diagnostic accuracy

Medicine (Baltimore), 2022-09, Vol.101 (38), p.e30683-e30683

2022

Volltextzugriff (PDF)

Iterative Feature eXclusion (IFX): Mitigating feature starvation in gradient boosted decision trees

Knowledge-based systems, 2024-04, Vol.289, p.111546, Article 111546

2024

Volltextzugriff (PDF)

AB0356 THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1304-1305

2022

Volltextzugriff (PDF)

EP1311: LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS FOLLOWING A SIMPLIFIED PROACTIVE DRUG MONITORING ALGORITHM DURING INDUCTION TREATMENT WITH INFLIXIMAB (IFX)

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-1097

2022

Volltextzugriff (PDF)

The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients

Journal of Crohn's and colitis, 2024-08, Vol.18 (7), p.1102-1112

2024

Volltextzugriff (PDF)

Quantifizierende Kontrastmittelsonografie (DCE-US) zur frühen Beurteilung des Therapienanprechens bei Patienten mit Chronisch Entzündlichen Darmerkrankungen (CED) unter Therapie mit Infliximab (IFX)

Zeitschrift für Gastroenterologie, 2018, Vol.56 (8), p.e206-e207

2018

Volltextzugriff (PDF)

S700 Early Proactive IFX Dose Optimization Negates the Impact of HLA-DQA105 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S317-S318

2021

Volltextzugriff (PDF)

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments

Medicine (Baltimore), 2020-07, Vol.99 (30), p.e21151

2020

Volltextzugriff (PDF)

P960 Comparison of clinical outcomes by induction therapy response status in patients with Inflammatory Bowel Disease (IBD) treated with subcutaneous (SC) versus intravenous (IV) infliximab (IFX): Post hoc analysis of a pivotal, randomised controlled trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1743-i1744

2024

Volltextzugriff (PDF)

P430 The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i883-i884

2024

Volltextzugriff (PDF)

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Blood, 2020-11, Vol.136 (Supplement 1), p.5-6

2020

Volltextzugriff (PDF)

Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy

Inflammatory bowel diseases, 2021-02, Vol.27 (2), p.224-235

2021

Volltextzugriff (PDF)

Abstract CT241: Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT241-CT241

2020

Volltextzugriff (PDF)

Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments

Medicine (Baltimore), 2020-08, Vol.99 (32), p.e21480-e21480

2020

Volltextzugriff (PDF)

Measurements and simulations of surface radiation damage effects on IFX and HPK test structures

Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment, 2020-04, Vol.958, p.162794, Article 162794

2020

Volltextzugriff (PDF)

Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

Expert opinion on biological therapy, 2021-01, Vol.21 (1), p.97-104

2021

Volltextzugriff (PDF)

Abstract CT119: Trial in progress: First in human Phase I study using a plasmid DNA coding for Emm55 streptococcal antigen (IFx-Hu2.0) in patients with unresectable stage III or stage IV cutaneous melanoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT119-CT119

2019

Volltextzugriff (PDF)

1 – 25 von 47.477

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28.215)
Mit Volltextzugriff
(34.171)

Publikationsform

8 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(46.451)
Deutsch
(389)
Spanisch
(202)
Japanisch
(143)
Französisch
(134)
Chinesisch
(71)
Portugiesisch
(71)
Koreanisch
(44)
Latein
(38)
Arabisch
(29)
Italienisch
(27)
Türkisch
(26)
Ungarisch
(19)
Hindi
(16)
Russisch
(12)
Urdu
(8)
Hebräisch
(6)
Serbian
(6)
Niederländisch
(5)

14 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(22.504)
Mathematics
(11.472)
Physical Sciences
(10.214)
Technology
(8.349)
Life Sciences & Biomedicine
(6.543)
Computer Science
(5.677)
Mathematics, Applied
(4.662)
Engineering
(4.516)
Mathematics And Statistics
(4.302)
Algorithms
(3.952)
Humans
(3.932)
Optimization
(2.431)
Infliximab
(2.265)
Analysis
(2.262)
Artificial Intelligence
(2.100)
Female
(2.020)
Physics
(2.000)
Computer Science, Artificial Intelligence
(1.994)
Male
(1.922)
Gastroenterology & Hepatology
(1.909)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Springer Online Journals Complete
(12.406)
IngentaConnect
(12.401)
EZB Electronic Journals Library
(10.819)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(8.390)
Journals@Ovid Ovid Full Text
(8.024)
ProQuest Dissertations & Theses A&I
(7.128)
IngentaConnect Journals
(5.903)
Ebook Central Perpetual and DDA
(4.508)
eBooks on EBSCOhost
(4.421)
MEDLINE
(4.234)
Nexis Uni
(3.654)
Business Source Ultimate
(2.780)
Wiley Online Library All Journals
(2.076)
Single Journals
(1.916)
JSTOR Archive Collection A-Z Listing
(1.633)
ScienceDirect Journals (5 years ago - present)
(1.626)
Oxford Journals Current Collection
(1.252)
Taylor & Francis Journals Auto-Holdings Collection
(1.175)
Springer Book Series
(1.103)
Taylor & Francis Current Content Access
(1.101)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab

Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC)

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Mo1847 THE INFLUENCE OF PERSISTENT ACTIVE INFLAMMATION ON IFX PHARMACOKINETIC MODELING AND DISEASE PROGRESSION ASSESSMENT: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY IN INFLAMMATORY BOWEL DISEASE PATIENTS

Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma

Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1

IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach

Performance of Remsima® Monitor Drug Level versus RIDASCREEN IFX Monitoring in therapeutic drug monitoring of infliximab in patients with inflammatory bowel disease: A study of diagnostic accuracy

Iterative Feature eXclusion (IFX): Mitigating feature starvation in gradient boosted decision trees

AB0356 THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM

EP1311: LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS FOLLOWING A SIMPLIFIED PROACTIVE DRUG MONITORING ALGORITHM DURING INDUCTION TREATMENT WITH INFLIXIMAB (IFX)

The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients

Quantifizierende Kontrastmittelsonografie (DCE-US) zur frühen Beurteilung des Therapienanprechens bei Patienten mit Chronisch Entzündlichen Darmerkrankungen (CED) unter Therapie mit Infliximab (IFX)

S700 Early Proactive IFX Dose Optimization Negates the Impact of HLA-DQA105 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases

P960 Comparison of clinical outcomes by induction therapy response status in patients with Inflammatory Bowel Disease (IBD) treated with subcutaneous (SC) versus intravenous (IV) infliximab (IFX): Post hoc analysis of a pivotal, randomised controlled trial

P430 The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Distribution and Cytokine Profile of Peripheral B Cell Subsets Is Perturbed in Pediatric IBD and Partially Restored During a Successful IFX Therapy

Abstract CT241: Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma

Measurements and simulations of surface radiation damage effects on IFX and HPK test structures

Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

Abstract CT119: Trial in progress: First in human Phase I study using a plasmid DNA coding for Emm55 streptococcal antigen (IFx-Hu2.0) in patients with unresectable stage III or stage IV cutaneous melanoma

Suchergebnisse filtern